紧急例外知情同意下复苏试验中通知入组时间与退出率的差异
该研究对五项在紧急例外知情同意(EFIC)下开展的试验进行事后描述性分析,纳入美国与加拿大Resuscitation Outcomes Consortium的院外心脏骤停或致命性创伤患者共35,442例(心脏骤停33,805例,创伤1,636例)。通知时间(TTN)定义为随机化至首次报告通知患者或法定代理人入组的时间,各中心间差异显著:心脏骤停中位TTN从6天(5%ile 1,95%ile 27)到28天(2,53)不等;创伤从0天(0,5)到36天(5,68)不等。通知后退出率心脏骤停为0.3%,创伤为7.7%。结论认为EFIC试验中TTN变异大,总体退出率低,提示现行EFIC实践对参与者可接受。
要点
- 在EFIC下开展的复苏试验中,通知入组时间(TTN)在各中心间差异巨大:心脏骤停中位6-28天,创伤中位0-36天。
- 通知后退出率总体较低:心脏骤停患者仅0.3%退出,创伤患者7.7%退出。
- TTN的变异可能源于多种因素,且可能可修改也可能不可修改,但原文未具体说明因素。
- 该研究为事后描述性分析,不能推断TTN与退出率之间的因果关系,也不能据此设定TTN的决策阈值。
- 现有数据提示EFIC相关实践对参与紧急研究的患者及其法定代理人而言是可接受的。
适用人群与场景
- 纳入:美国与加拿大Resuscitation Outcomes Consortium参与中心收治的院外心脏骤停或致命性创伤患者,共35,442例(心脏骤停33,805例,创伤1,636例)。
- 场景:紧急医疗服务(EMS)及接收医院,试验在EFIC下进行。
- 排除人群:原文未提及。
诊断标准与关键阈值
- EFIC试验需满足特定标准方可开展,包括入组后通知患者或法定代理人,但原文未列出具体标准条目。
- 通知时间(TTN)定义为从随机化至首次报告通知患者或法定代理人入组的时间。
- 退出定义为通知时患者或法定代理人选择退出继续参与。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:对五项EFIC试验的事后描述性分析;样本量35,442例(心脏骤停33,805例,创伤1,636例);中心数原文未提及;人群为院外心脏骤停或致命性创伤患者。
- 干预与对照:无干预对照,各中心在入组前由当地IRB指定通知策略,研究期间中央监测TTN。
- 主要终点:TTN在各中心间差异显著;心脏骤停中位TTN范围6天(5%ile 1,95%ile 27)至28天(2,53);创伤中位TTN范围0天(0,5)至36天(5,68)。
- 关键次要终点:通知后退出率心脏骤停0.3%,创伤7.7%。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:对五项EFIC试验的事后描述性分析(非随机对照试验)。
- 证据等级或推荐强度:原文未提及。
- 局限:事后分析、描述性设计,无法推断因果关系;中心数和具体通知策略细节原文未提供;TTN变异因素未明确。
对床旁实践的改变
- 该研究提示在EFIC下开展的紧急复苏试验中,通知入组时间存在较大中心间差异,但通知后退出率低,支持现行EFIC实践的可接受性。
- 适用人群:院外心脏骤停或致命性创伤患者参与的EFIC试验;不适用人群:原文未提及。
- 常见陷阱:不能将TTN的观察性范围(如心脏骤停6-28天)作为决策阈值或质量指标;退出率低不等于可省略通知或知情过程。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Emergency research is challenging to do well as it involves time sensitive interventions in unstable patients. There is limited time to obtain informed consent from the patient or their legally authorized representative (LAR). Such research is permitted under exception from informed consent (EFIC) if specific criteria are met, including notification after enrollment. Some question whether the risks of EFIC outweighs its benefits. To date, there is limited empiric information about time to notification (TTN) and rates of withdrawal in such trials.
OBJECTIVE: To describe variation in TTN and rates of withdrawal among that patients enrolled in EFIC trials over a twelve-year period.
DESIGN: We performed post hoc descriptive analyses of data from five trials conducted under EFIC.
SETTING: Emergency medical services and receiving hospitals participating in the Resuscitation Outcomes Consortium in the United States and Canada.
PARTICIPANTS: Patients with out-of-hospital cardiac arrest or life-threatening traumatic injury.
EXPOSURES: Notification strategies were specified at each site before initiation of enrollment by a local institutional review board. We monitored TTN within each site centrally throughout each study's enrollment period.
OUTCOMES: TTN was defined as time from randomization to first-reported notification of patient or LAR of enrollment. Withdrawal was defined as patient or LAR opt out of ongoing participation at the time of notification.
RESULTS: Of 35,442 patients enrolled in five trials, 33,805 had cardiac arrest; and 1636 had traumatic injury. TTN varied overall and by patient outcome. Among those with cardiac arrest, TTN ranged from median (5%ile, 95%ile) of 6 (1,27) days to 28 (2, 53) days across sites. 0.3% of notified patients with cardiac arrest withdrew. Among those with traumatic injury, TTN ranged from 0 (0, 5) days to 36 (5, 68) days across sites. 7.7% of notified patients with traumatic injury withdrew.
CONCLUSIONS AND RELEVANCE: There is large variation in TTN in trials conducted under EFIC for emergency research. This may be due to several factors. It may or may not be modifiable. Overall rates of withdrawal are low, which suggests current practices related to EFIC are acceptable to those who have participated in emergency research.
参考来源
- Nichol G, Zhuang R, Russell R, et al. Variation in time to notification of enrollment and rates of withdrawal in resuscitation trials conducted under exception from informed consent. Resuscitation. 2021. PMID: 34384820. doi:10.1016/j.resuscitation.2021.07.039
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。